Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PulmoBind for Molecular Imaging of Pulmonary Hypertension
NCT02216279Phase 2Completed
- Sponsor
- Montréal Heart Institute
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PulmoBind in pulmonary hypertension (PH) (2 arms), sponsored by Montréal Heart Institute. Primary endpoints: Absence of allergic reaction after repeated exposures, Safety of PulmoBind in participants diagnosed with pulmonary hypertension and 1 more. Started Sep 2014; status: completed.
02
Drugs
PulmoBind
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02216279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216279.